Browse diseases

…, monitoring, and treatment needs to be established. Given that MASLD is a multisystem disease, assessing cost effectiveness should c…

…ction may be indicated to achieve greater therapeutic benefit B.Obesity is a heterogeneous disease with varying effects on health, nece…

…Background Metabolic dysfunction-associated steatotic liver disease and its more severe manifestation, metabolic dysfunction-associ…

…), metabolic-associated steatohepatitis (MASH), and the risk of colorectal cancer (CRC) and benign colorectal neoplasms (BCN), and to explore whe…

…bule. It showed that inflammation burden was higher in AIH than MASLD/MASH, despite equivalent portal grades, providing objective sup…

…trate clinical benefit in MAESTRO-NASH OUTCOMES, an ongoing 845 MASH cirrhosis patient clinical outcome study.…

…Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than a third of the world’s adult population, maki…

…, and the authors tested the diagnostic performance for at-risk MASH and advanced fibrosis using area under the curve analysis. TSP2…

…ract P60 Figure 1Cumulative incidence functions (CIFs) for MASL/MASH progression to cirrhosis and composite events stratified by the…

…lic steatohepatitis (NASH), is the hepatic manifestation of the metabolic syndrome. When it co-occurs with type 2 diabetes (T2DM), it presents a s…

…n shown to be protective against development and progression of hepatocellular carcinoma (HCC). We investigated in human in vitro models of pre-cancerou…

…iopsy-proven F2/F3 fibrosis. Co-morbidities such as obesity and T2DM are common in patients with MASH and may be treated with glucag…